跳至主要内容
临床试验/KCT0001828
KCT0001828招募中未知

A double blind, randomized, active-controlled, phase 3 study to evaluate the safety and efficacy of CJ-12420 in patients with erosive esophagitis

CJ Healthcare0 个研究点目标入组 280 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
CJ Healthcare
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20(Year) 至 70(Year)(—)
性别
All

入选标准

  • Subjects aged between 20 and 70 years
  • Subjects who had experienced heartburn and regurgitation within 7 days before visit 1. Entry into study also required that patients had experienced at least mild upper gastrointestinal symptoms on at least 2 days/week or at least moderate upper gastrointestinal symptoms on at least 1 day/week
  • Endoscopically confirmed erosive esophagitis as defined by LA Classification Grading System (A-D) within
  • 14 days prior to randomization

排除标准

  • Subjects who cannot undergo EGD
  • Subjects diagnosed with primary esophageal motility disorder, IBS, IBD, etc. or with suspected IBS in the
  • last 3 months
  • Subjects who took Proton Pump Inhibitor(PPI) within 2 weeks prior to endoscopy
  • Long-term use of nonsteroidal anti-inflammatory drugs throughout the study
  • Subjects with the following clinically significant laboratory abnormalitues:
  • - AST or ALT or ALP or GGT or total bilirubin >2 x Upper Limit Normal (ULN)
  • - BUN or Creatinine >1.5 ULN

研究者

发起方
CJ Healthcare

相似试验

已完成
1 期
A study to evaluate an mRNA COVID-19 vaccine (IN002.5.1) in comparison with an approved mRNA COVID-19 vaccine
ACTRN12622001415796Shenzhen Shenxin Biotechnology Co., Ltd.56
进行中(未招募)
1 期
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteoporosis.Osteoporosis is a systemic skeletal disease that is characterized by low bone mass and micro architectural deterioration of bone tissue, with a low bone mineral density (BMD) and consequent increase in bone fragility and susceptibility to fracture. The incidence of fractures varies greatly by country, but on average up to 50% of women > 50 years of age are at risk of fractures. Postmenopausal osteoporosis, resulting from estrogen deficiency, is the most common type of osteoporosis.MedDRA version: 20.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2020-005974-91-LVCelltrion, Inc440
进行中(未招募)
1 期
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteoporosis.
EUCTR2020-005974-91-EECelltrion, Inc440
进行中(未招募)
3 期
Double-blind comparison of Chronocort versus standard hydrocortisonereplacement therapy in participants aged 16 years and over with congenital adrenalhyperplasia
JPRN-jRCT2031210491Fujii Katsuya15
已完成
3 期
A Randomized, Double-blind, Active-controlled, Phase 3 study evaluating the Efficacy and Safety of ABP 959 compared with Eculizumab in Adult Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)
NL-OMON50383Amgen2